The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Chemical modification: the key to clinical application of RNA interference?
Open accessAbstract
RNA interference provides a potent and specific method for controlling gene expression in human cells. To translate this potential into a broad new family of therapeutics, it is necessary to optimize the efficacy of the RNA-based drugs. As discussed in this Review, it might be possible to achieve this optimization using chemical modifications that improve their in vivo stability, cellular delivery, biodistribution, pharmacokinetics, potency, and specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA
Chow, L. T., Gelinas, R. E., Broker, T. R., & Roberts, R. J. (1977) · Cell · doi:10.1016/0092-8674(77)90180-5 · Cited by 1,234
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Perspective: machines for RNAi
Tomari, Y., & Zamore, P. D. (2005) · Genes & Development · doi:10.1101/gad.1284105 · Cited by 948
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Morpholino antisense oligomers: the case for an RNase H-independent structural type
Summerton, J. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00150-5 · Cited by 664
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg393 · Cited by 623
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Self-citationIn vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Sharp, P. (1994) · Cell · doi:10.1016/0092-8674(94)90130-9 · Cited by 567
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
Elm n, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki193 · Cited by 559
Tolerance for mutations and chemical modifications in a siRNA
Amarzguioui, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg147 · Cited by 534
RNA Interference in Mammalian Cells by Chemically-Modified RNA
Braasch, D. A., Jensen, S., Liu, Y., Kaur, K., Arar, K., White, M. A., & Corey, D. R. (2003) · Biochemistry · doi:10.1021/bi0343774 · Cited by 531
Self-citationRNAi: The Nuts and Bolts of the RISC Machine
Filipowicz, W. (2005) · Cell · doi:10.1016/j.cell.2005.06.023 · Cited by 482
Oishi, M., Nagasaki, Y., Itaka, K., Nishiyama, N., & Kataoka, K. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044941d · Cited by 476
Harborth, J., Elbashir, S. M., Vandenburgh, K., Manninga, H., Scaringe, S. A., Weber, K., & Tuschl, T. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003321629638 · Cited by 474
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 438
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 433
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells
Muratovska, A., & Eccles, M. R. (2004) · FEBS Letters · doi:10.1016/s0014-5793(03)01505-9 · Cited by 390
Gleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
RNA interference using boranophosphate siRNAs: structure-activity relationships
Hall, A. H. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh936 · Cited by 285
Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells
Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050044o · Cited by 285
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.023 · Cited by 273
Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Kim, W. J., Christensen, L. V., Jo, S., Yockman, J. W., Jeong, J. H., Kim, Y.-H., & Kim, S. W. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.022 · Cited by 251
Biodistribution of phosphodiester and phosphorothioate siRNA
Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Öz, O. K., Mason, R. P., & Corey, D. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.074 · Cited by 251
Self-citationNovel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression
Braasch, D. A., & Corey, D. R. (2002) · Biochemistry · doi:10.1021/bi0122112 · Cited by 248
Self-citationA brief history of RNAi: the silence of the genes
Sen, G. L., & Blau, H. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-6014rev · Cited by 245
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting
De Paula, D., Bentley, M. V. L. B., & Mahato, R. I. (2007) · RNA · doi:10.1261/rna.459807 · Cited by 228
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225
Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro- -D-arabinonucleic acid (FANA)
Dowler, T. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl033 · Cited by 188
Manoharan, M. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760070849 · Cited by 185
Evaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo
Mook, O. R., Baas, F., de Wissel, M. B., & Fluiter, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0195 · Cited by 182
Kraynack, B. A., & Baker, B. F. (2005) · RNA · doi:10.1261/rna.2150806 · Cited by 159
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA
Fattal, E., & Bochot, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.020 · Cited by 152
Gene Silencing by Double‐Stranded RNA (Nobel Lecture)
Fire, A. Z. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701979 · Cited by 151
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway
John, M., Constien, R., Akinc, A., Goldberg, M. S., Moon, Y.-A., Spranger, M., Hadwiger, P., Soutschek, J., Vornlocher, H., Manoharan, M., et al. (2007) · Nature · doi:10.1038/nature06179 · Cited by 144
Dande, P., Prakash, T. P., Sioufi, N. B., Gaus, H. J., Jarres, R., Berdeja, A., Swayze, E. E., Griffey, R. H., & Bhat, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050822c · Cited by 138
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 133
High potency silencing by single-stranded boranophosphate siRNA
Hall, A., Wan, J., Spesock, A., Sergueeva, Z. A., Shaw, B. R., & Alexander, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl339 · Cited by 124
Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)
Watanabe, T. A., Geary, R. S., & Levin, A. A. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.169 · Cited by 120
KISS: The kinetoplastid RNA editing sequence search tool
Ochsenreiter, T., Cipriano, M. J., & Hajduk, S. L. (2006) · RNA · doi:10.1261/rna.232907 · Cited by 118
Competition for RISC binding predicts in vitro potency of siRNA
Koller, E., Propp, S. S., Murray, H., Lima, W. F., Bhat, B., Prakash, T. P., Allerson, C. R., Swayze, E. E., Marcusson, E. G., & Dean, N. M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl589 · Cited by 115
Corey, D. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0107-8 · Cited by 97
Self-citationDesign and cloning of lentiviral vectors expressing small interfering RNAs
Tiscórnia, G., Singer, O., & Verma, I. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.36 · Cited by 96
RNA interference induced by siRNAs modified with 4′‐thioribonucleosides in cultured mammalian cells
Hoshika, S., Minakawa, N., Kamiya, H., Harashima, H., & Matsuda, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.04.073 · Cited by 94
Gene Silencing Activity of siRNAs with a Ribo-difluorotoluyl Nucleotide
Xia, J. L., Noronha, A. M., Toudjarska, I., Li, F., Akinc, A., Braich, R. S., Frank-Kamenetsky, M. D., Rajeev, K. G., Egli, M., & Manoharan, M. (2006) · ACS Chemical Biology · doi:10.1021/cb600063p · Cited by 93
Deletion of cytosolic phospholipase A2 promotes striated muscle growth
Haq, S., Kilter, H., Michael, A., Tao, J., O’Leary, E., Sun, X. M., Walters, B. M., Bhattacharya, K., Chen, X., Cui, L., et al. (2003) · Nature Medicine · doi:10.1038/nm891 · Cited by 89
2′-Fluoro-4′-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity
Watts, J. K., Choubdar, N., Sadalapure, K., Robert, F., Wahba, A. S., Pelletier, J., Pinto, B. M., & Damha, M. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1153 · Cited by 89
Self-splicing and enzymatic activity of an intervening sequence RNA from Tetrahymena
Cech, T. R. (1990) · Bioscience Reports · doi:10.1007/bf01117241 · Cited by 75
Intracellular Uptake and Inhibition of Gene Expression by PNAs and PNA−Peptide Conjugates
Kaihatsu, K., Huffman, K. E., & Corey, D. R. (2004) · Biochemistry · doi:10.1021/bi048519l · Cited by 70
Self-citationGrillone, L. R., & Lanz, R. (2001) · Drugs of today · doi:10.1358/dot.2001.37.4.620590 · Cited by 69
Developments in RNA chemistry, a personal view
Eckstein, F. (2002) · Biochimie · doi:10.1016/s0300-9084(02)01459-1 · Cited by 68
Whelan, J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03547-6 · Cited by 64
Return to the RNAi World: Rethinking Gene Expression and Evolution (Nobel Lecture)
Mello, C. C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701713 · Cited by 58
Geary, R. S., Bradley, J. D., Watanabe, T. A., et al. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00003 · Cited by 50
Enzymatic cleavage of RNA by RNA
Altman, S. (1990) · Bioscience Reports · doi:10.1007/bf01117232 · Cited by 49
Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis
Hadj-Slimane, R., Lepelletier, Y., LOPEZ, N., Garbay, C., & Raynaud, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.06.012 · Cited by 48
Chemical Modifications Rescue Off-Target Effects of RNAi
Snøve, O., & Rossi, J. J. (2006) · ACS Chemical Biology · doi:10.1021/cb6002256 · Cited by 41
Technology evaluation: ISIS-113715, Isis.
Liu, G. (2004) · PubMed · Cited by 39
Janowski, B. A., Hu, J., & Corey, D. R. (2006) · Nature Protocols · doi:10.1038/nprot.2006.64 · Cited by 38
Self-citationAntisense apolipoprotein B therapy: where do we stand?
Akdim, F., Stroes, E. S. G., & Kastelein, J. J. P. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328248b4ad · Cited by 33
Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era.
Juliano, R. L., Astriab‐Fisher, A., & Falke, D. (2001) · PubMed · Cited by 30
The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer
Miyake, H., Hara, I., Fujisawa, M., & Gleave, M. E. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.507 · Cited by 29
Self-Splicing and Enzymatic Activity of an Intervening Sequence RNA from Tetrahymena
Cech, T. R. (2004) · Bioscience Reports · doi:10.1007/s10540-005-2738-3 · Cited by 23
Rusckowski, M., QU, T., Roskey, A., & Agrawal, S. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.333 · Cited by 20
Cited by
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Self-citationChemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Metadata
- Authors
- Corey, D. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-12-03
- Volume
- 117
- Issue
- 12
- Pages
- 3615-3622
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1988471700
- Cited by
- 285
- References
- 85
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.